Novartis | NVS - Trade Creditors


Novartis reported $4.32B in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Amgen USD 19.52B 1.37B Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
Bausch Health Companies USD 593M 7M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Canopy Growth CAD 34.82M 14.85M Mar/2026
Corcept Therapeutics USD 33.31M 7.14M Mar/2026
Drreddys Laboratories INR 22.36B 21.91B Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Merck USD 3.86B 541M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Pacira USD 14.01M 1.14M Mar/2026
Perrigo USD 434.8M 39.7M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Phibro Animal Health USD 129.64M 3.65M Mar/2026
Prestige Brands USD 22.79M 20.15M Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sanofi EUR 22.71B 219M Mar/2026
Sanofi EUR 22.71B 219M Mar/2026
Supernus Pharmaceuticals USD 10.17M 97.63M Mar/2026
Zoetis USD 507M 20M Mar/2026